Ginkgo Bioworks Holdings, Inc. Logo

Ginkgo Bioworks Holdings, Inc.

A cell programming platform offering R&D services for pharma, agriculture, food, and chemicals.

DNA | US

Overview

Corporate Details

ISIN(s):
KYG8354H1267 (+2 more)
LEI:
Country:
United States of America
Address:
27 DRYDOCK AVENUE, 2210 BOSTON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ginkgo Bioworks Holdings, Inc. is a synthetic biology company that operates a leading horizontal platform for cell programming. Its core mission is to make biology easier to engineer, enabling customers to program cells with the ease of programming computers. The company's platform leverages high-throughput automation, proprietary software, artificial intelligence, and an extensive biological codebase to design, build, and test custom organisms for its partners. Ginkgo provides flexible, end-to-end R&D services to solve challenges across diverse markets, including pharmaceuticals, agriculture, food and nutrition, and specialty chemicals, facilitating the development of novel and more sustainable products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ginkgo Bioworks Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ginkgo Bioworks Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ginkgo Bioworks Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Digital brain health assessment platform for CNS clinical trials and research.
United Kingdom
COG
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium
CYAD

Talk to a Data Expert

Have a question? We'll get back to you promptly.